Skip to main content
Blinatumomab may benefit youths with B-cell ALL

Researchers found that children and young adults with intermediate- and high-risk B-cell acute lymphoblastic leukemia who received blinatumomab after induction therapy had significantly improved two-year, progression-free and overall survival compared with those who were given chemotherapy. The findings were presented at the American Society of Hematology's annual meeting.

Full Story: